The United Kingdom and the United States have finalized a major commercial pact that will maintain zero duties on UK drug exports being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the National Health Service (NHS). This move ensures that duties on these crucial products will remain at zero for a period of 36 months.
This development is in response to recent threats to dramatically increase import taxes on branded pharmaceutical products, with increases mentioned reaching 100%.
"This deal between the Britain reinforces the global environment for innovative medicines and establishes long-overdue balance to American-British pharmaceutical trade," a release said.
Trade Importance
Pharmaceuticals represent one of the Britain's largest goods shipped to the America, which is clearly the largest destination for major UK drugmakers.
Trade data reveal that in the one-year period prior to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This deal protects employment, stimulates capital expenditure and facilitates the UK to emerge as a global hub for medical research," a minister commented.
Detailed British Pledges
The deal involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall public funding on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount manufacturers must return to the NHS to control costs will be capped at 15%. In the past, refunds topped twenty percent.
Industry Background
The pact comes amid a long-running row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were heightened by arguments that US patients were paying several times more for the identical medicines than people in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been delayed or cancelled, while major funding commitments have been pledged toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its resources over the past decade.
